Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Feb;34(2):242–246. doi: 10.1136/gut.34.2.242

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.

W J Sandborn 1, R H Wiesner 1, W J Tremaine 1, N F Larusso 1
PMCID: PMC1373978  PMID: 8432481

Abstract

Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88%) v 9/10 (90%), and moderate colitis, 2/16 (12%) v 1/10 (10%). During treatment, a remission/mild disease course was present in 15/16 (94%) v 6/10 (60%), p = 0.05 and a moderate disease course in 1/16 (6%) v 4/10 (40%), p = 0.05. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis.

Full text

PDF
242

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aadland E., Schrumpf E., Fausa O., Elgjo K., Heilo A., Aakhus T., Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol. 1987 Aug;22(6):655–664. doi: 10.3109/00365528709011139. [DOI] [PubMed] [Google Scholar]
  2. Allison M. C., Pounder R. E. Cyclosporin for Crohn's disease. Aliment Pharmacol Ther. 1987 Feb;1(1):39–43. doi: 10.1111/j.1365-2036.1987.tb00604.x. [DOI] [PubMed] [Google Scholar]
  3. BARON J. H., CONNELL A. M., LENNARD-JONES J. E. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89–92. doi: 10.1136/bmj.1.5375.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bianchi Porro G., Petrillo M., Ardizzone S. Cyclosporin treatment for severe active ulcerative colitis. Lancet. 1990 Aug 18;336(8712):439–439. doi: 10.1016/0140-6736(90)91984-i. [DOI] [PubMed] [Google Scholar]
  5. Brynskov J., Binder V., Riis P., Lauritsen K., Schaffalitzky de Muckadell O., Freund L., Fallingborg J., Nørby Rasmussen S., Matzen P., Krag E. Low-dose cyclosporin for Crohn's disease: implications for clinical trials. Aliment Pharmacol Ther. 1989 Apr;3(2):135–142. doi: 10.1111/j.1365-2036.1989.tb00199.x. [DOI] [PubMed] [Google Scholar]
  6. Brynskov J., Freund L., Rasmussen S. N., Lauritsen K., de Muckadell O. S., Williams N., MacDonald A. S., Tanton R., Molina F., Campanini M. C. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med. 1989 Sep 28;321(13):845–850. doi: 10.1056/NEJM198909283211301. [DOI] [PubMed] [Google Scholar]
  7. Brynskov J., Freund L., Thomsen O. O., Andersen C. B., Rasmussen S. N., Binder V. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet. 1989 Apr 1;1(8640):721–722. doi: 10.1016/s0140-6736(89)92232-0. [DOI] [PubMed] [Google Scholar]
  8. Brynskov J., Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut. 1990 Jul;31(7):795–799. doi: 10.1136/gut.31.7.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chapman R. W., Arborgh B. A., Rhodes J. M., Summerfield J. A., Dick R., Scheuer P. J., Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980 Oct;21(10):870–877. doi: 10.1136/gut.21.10.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cockburn I. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune. Transplant Proc. 1987 Feb;19(1 Pt 2):1804–1807. [PubMed] [Google Scholar]
  11. Dougados M., Awada H., Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis. 1988 Feb;47(2):127–133. doi: 10.1136/ard.47.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ellis C. N., Gorsulowsky D. C., Hamilton T. A., Billings J. K., Brown M. D., Headington J. T., Cooper K. D., Baadsgaard O., Duell E. A., Annesley T. M. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986 Dec 12;256(22):3110–3116. [PubMed] [Google Scholar]
  13. Fukushima T., Sugita A., Masuzawa S., Yamazaki Y., Tsuchiya S. Effects of cyclosporin A on active Crohn's disease. Gastroenterol Jpn. 1989 Feb;24(1):12–15. doi: 10.1007/BF02774864. [DOI] [PubMed] [Google Scholar]
  14. Gupta S., Keshavarzian A., Hodgson H. J. Cyclosporin in ulcerative colitis. Lancet. 1984 Dec 1;2(8414):1277–1278. doi: 10.1016/s0140-6736(84)92826-5. [DOI] [PubMed] [Google Scholar]
  15. Helzberg J. H., Petersen J. M., Boyer J. L. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology. 1987 Jun;92(6):1869–1875. doi: 10.1016/0016-5085(87)90618-4. [DOI] [PubMed] [Google Scholar]
  16. Hess A. D., Tutschka P. J., Santos G. W. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol. 1982 Jan;128(1):355–359. [PubMed] [Google Scholar]
  17. Hyams J. S., Ballow M., Leichtner A. M. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987 Oct;93(4):890–893. doi: 10.1016/0016-5085(87)90454-9. [DOI] [PubMed] [Google Scholar]
  18. Hyams J. S., Treem W. R. Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr. 1989 Oct;9(3):383–387. doi: 10.1097/00005176-198910000-00020. [DOI] [PubMed] [Google Scholar]
  19. Lichtiger S., Present D. H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990 Jul 7;336(8706):16–19. doi: 10.1016/0140-6736(90)91521-b. [DOI] [PubMed] [Google Scholar]
  20. MacDermott R. P. Cell-mediated immunity in gastrointestinal disease. Hum Pathol. 1986 Mar;17(3):219–233. doi: 10.1016/s0046-8177(83)80215-9. [DOI] [PubMed] [Google Scholar]
  21. Nussenblatt R. B., Palestine A. G., Chan C. C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275–282. doi: 10.1016/s0002-9394(14)77814-6. [DOI] [PubMed] [Google Scholar]
  22. Nyberg A., Löf L. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol. 1989 Jan;24(1):57–64. doi: 10.3109/00365528909092240. [DOI] [PubMed] [Google Scholar]
  23. Olsson R., Danielsson A., Järnerot G., Lindström E., Löf L., Rolny P., Rydén B. O., Tysk C., Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991 May;100(5 Pt 1):1319–1323. [PubMed] [Google Scholar]
  24. Palestine A. G., Nussenblatt R. B., Chan C. C. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984 Oct;77(4):652–656. doi: 10.1016/0002-9343(84)90356-5. [DOI] [PubMed] [Google Scholar]
  25. Parrott N. R., Taylor R. M., Venables C. W., Record C. O. Treatment of Crohn's disease in relapse with cyclosporin A. Br J Surg. 1988 Dec;75(12):1185–1188. doi: 10.1002/bjs.1800751213. [DOI] [PubMed] [Google Scholar]
  26. Ranzi T., Campanini M. C., Velio P., Quarto di Palo F., Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet. 1989 Jul 8;2(8654):97–97. doi: 10.1016/s0140-6736(89)90330-9. [DOI] [PubMed] [Google Scholar]
  27. Sawchuk R. J., Cartier L. L. Liquid-chromatographic determination of cyclosporin A in blood and plasma. Clin Chem. 1981 Aug;27(8):1368–1371. [PubMed] [Google Scholar]
  28. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  29. Schrumpf E., Fausa O., Kolmannskog F., Elgjo K., Ritland S., Gjone E. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol. 1982 Jan;17(1):33–39. doi: 10.3109/00365528209181041. [DOI] [PubMed] [Google Scholar]
  30. Shelley E. D., Shelley W. B. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol. 1988 May;18(5 Pt 1):1084–1088. doi: 10.1016/s0190-9622(88)70111-5. [DOI] [PubMed] [Google Scholar]
  31. Stange E. F., Fleig W. E., Rehklau E., Ditschuneit H. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci. 1989 Sep;34(9):1387–1392. doi: 10.1007/BF01538074. [DOI] [PubMed] [Google Scholar]
  32. TRUELOVE S. C., HAMBLING M. H. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J. 1958 Nov 1;2(5104):1072–1077. doi: 10.1136/bmj.2.5104.1072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tegzess A. M., Doorenbos B. M., Minderhoud J. M., Donker A. J. Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporine A. Transplant Proc. 1988 Apr;20(2 Suppl 2):390–393. [PubMed] [Google Scholar]
  34. Tindall R. S., Rollins J. A., Phillips J. T., Greenlee R. G., Wells L., Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987 Mar 19;316(12):719–724. doi: 10.1056/NEJM198703193161205. [DOI] [PubMed] [Google Scholar]
  35. Wiesner R. H., LaRusso N. F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980 Aug;79(2):200–206. [PubMed] [Google Scholar]
  36. Wiesner R. H., Ludwig J., Lindor K. D., Jorgensen R. A., Baldus W. P., Homburger H. A., Dickson E. R. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990 May 17;322(20):1419–1424. doi: 10.1056/NEJM199005173222003. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES